ArticleCancer research communications2024

Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Pamela Munster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.